olfactory receptor family 11 subfamily N member 1 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR11N1P profile across patient tissues and cancer cell-line models. OR11N1P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OR11N1P is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, OR11N1P RNA expression shows 10,354 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, and HNSC as cancer lineages where OR11N1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR11N1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR11N1P survival associations across molecular data types. OR11N1P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR11N1P RNA expression–survival associations across cancer types. High OR11N1P expression shows unfavorable associations in KIRC, STAD, HNSC, LUSC, SKCM and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for OR11N1P RNA expression.
This table summarizes OR11N1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR11N1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR11N1P shows higher tumor expression in HNSC, LUSC, STAD, LUAD and COAD. The HNSC box plot shows higher OR11N1P RNA expression in tumor versus normal tissue (log2 FC = +0.134, t-test p < 0.001).
This table shows molecular features associated with OR11N1P in patient tissues and cancer cell lines. In patient samples, OR11N1P shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
